R848 (Resiquimod), an imidazoquinoline, is a dual TLR8 and TLR7 synthetic agonist with potent antiviral activity. InvivoGen R848 (≥95% HPLC) is water soluble, functionally tested on TLR7 …

Resiquimod (R-848) is a drug that acts as an immune response modifier, and has antiviral and antitumour activity. It is used as a topical gel [1] in the treatment of skin lesions [2] such as …

Mar 14, 2025 · R848 is a synthetic agonist that activates Toll-like receptors 7 and 8 (TLR7/8), key components of the innate immune system. By stimulating these receptors, R848 initiates …

Resiquimod (R848) enhances PBL proliferation in a dose-dependent manner, and increases the number of BrdU-positive cells in BrdU incorporation assay. Cells treated with R848 exhibits …

Oct 15, 2019 · We demonstrate that TLR7/8 agonist R848 induces anti-tumor responses and attenuates cachexia in murine models of pancreatic ductal adenocarcinoma (PDAC).

R848 is an imidazoquinoline and agonist of Toll-like receptors (TLRs) 7 and 8. It mimics the pathogen-associated molecular patterns that activate immune cells through TLR7 and TLR8, …

Treatment with the Toll-like receptor 7 (TLR7) agonist, resiquimod (R848), is effective in various types of cancer, such as breast, pancreatic and colorectal cancer. The reported antitumor …

R848 (Resiquimod) is an imidazoquinoline compound with potent anti-viral activity1-3. This low molecular weight synthetic molecule is a selective activating ligand for both TLR7 and TLR8 in …

Resiquimod (R848) (GMP) is Resiquimod (HY-13740) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. …

Feb 1, 2025 · Toll-like receptor agonist (R848) nanoparticles for tumor-selective immunotherapy were synthesized through polyphenol-mediated assembly, a method that simplifies preparation …